Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for la...
Saved in:
Main Authors: | Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2014/617638 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Conversion to Sirolimus Therapy in Kidney Transplant Recipients with New Onset Diabetes Mellitus after Transplantation
by: Massimiliano Veroux, et al.
Published: (2013-01-01) -
Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation
by: Elizabeth J. Carey, et al.
Published: (2012-01-01) -
Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
by: Amir Sheikholeslami, et al.
Published: (2024-09-01) -
Sitagliptin: a potential drug for the treatment of COVID-19?
by: Bardaweel Sanaa K., et al.
Published: (2021-06-01) -
Transluminal Angioplasty of Transplanted Renal Artery Stenosis: A Review of the Literature for Its Safety and Efficacy
by: Polytimi Leonardou, et al.
Published: (2011-01-01)